Gillogly A, Kilbourn C, Waldvogel J, Martin J, Annich G, Wagner D
College of Pharmacy, University of Michigan, Ann Arbor, MI, USA.
Perfusion. 2013 Mar;28(2):141-5. doi: 10.1177/0267659112467825. Epub 2012 Nov 30.
Extracorporeal membrane oxygenation (ECMO) is a life support system used as a bridge to transplantation in critically ill patients who suffer from acute respiratory or cardiac failure with resultant hypoxemia and tissue hypoxia. This is not amendable to conventional support intervention. Previous studies have shown significant drug losses in the components of an ECMO circuit, leading to decreased plasma drug levels. An in vitro study was conducted to determine: (1) changes in intravenous acetaminophen levels over time and (2) changes in concentration observed between different sites of the ECMO circuit. A single bolus dose of intravenous (IV) acetaminophen was injected into a standard blood-primed ECMO circuit. Plasma drug concentrations in the circuit were then measured at specific time points at three different locations to determine concentrations of the drug at time 0, 15, 30, 60, 240 and 360 minutes. The three samples were drawn pre- and post-membrane oxygenator and the polyvinyl chloride (PVC) tubing. A second bolus dose was administered 24 hours after the first in order to compare "new" and "old" circuits. This entire process was repeated a total of three times. The results show that acetaminophen concentrations do not change significantly over time, with consistent levels seen in both new and old circuits (N=9). Average old circuit concentrations were approximately two times greater than the average new circuit concentrations after the circuit was re-dosed at 24 hours. Drug sequestration in the circuit was not significant in any of the three sites measured. It appears that, while acetaminophen levels remain relatively constant over a six hour period, dosing adjustments may be required for use in a circuit beyond the initial 24 hour period, depending on physiologic clearance of the drug. Assuming a six-hour dosing interval, levels should remain constant.
体外膜肺氧合(ECMO)是一种生命支持系统,用于作为患有急性呼吸或心力衰竭并伴有低氧血症和组织缺氧的重症患者移植的桥梁。这不适用于传统的支持干预。先前的研究表明,ECMO回路组件中存在大量药物损失,导致血浆药物水平降低。进行了一项体外研究以确定:(1)静脉注射对乙酰氨基酚水平随时间的变化,以及(2)ECMO回路不同部位之间观察到的浓度变化。将单次静脉推注剂量的对乙酰氨基酚注入标准血液预充的ECMO回路中。然后在三个不同位置的特定时间点测量回路中的血浆药物浓度,以确定在0、15、30、60、240和360分钟时药物的浓度。在膜式氧合器和聚氯乙烯(PVC)管路前后采集三个样本。在第一次给药24小时后给予第二次推注剂量,以比较“新”回路和“旧”回路。整个过程总共重复三次。结果表明,对乙酰氨基酚浓度随时间没有显著变化,新回路和旧回路中的水平一致(N = 9)。在24小时重新给药后,旧回路的平均浓度约为新回路平均浓度的两倍。在所测量的三个部位中的任何一个部位,回路中的药物螯合都不显著。似乎虽然对乙酰氨基酚水平在六小时内保持相对恒定,但根据药物的生理清除情况,在初始24小时之后的回路中使用时可能需要调整剂量。假设给药间隔为六小时,水平应保持恒定。